All posts related to "BC PharmaCare"

Tell BC PharmaCare: Support canakinumab therapy for children in need

Arthritis Consumer Experts and Cassie and Friends Society have launched a canakinumab access campaign. 

child with systemic juvenile idiopathic arthritisJuvenile arthritis (JA) affects approximately 24,000 infants to teens in BC and Canada, or 3 in every 1,000, making it one of the most common causes of chronic disability in children. Ten to 20 percent of those children have systemic juvenile idiopathic arthritis (sJIA), a severe and potentially life-threatening form of the disease – and many can’t get the medication they desperately need.

In partnership with Arthritis Consumer Experts, Cassie and Friends Society is leading a call for the BC Government to drastically improve the outlook of children with sJIA by allowing reimbursement coverage for canakinumab for the small number of children who need it.

Why have we launched our canakinumab access campaign?
Canakinumab is publicly funded in other Canadian provinces/territories but not BC, putting British Columbian children living with sJIA and other autoinflammatory diseases at a horrible disadvantage by denying them access to a life-changing therapy.
Continue reading

Let BC PharmaCare hear “Your Voice” on sarilumab

Stickman with megaphone calling for Your Voice patient inputBC PharmaCare is looking for your input on sarilumab for the treatment of rheumatoid arthritis

Sarilumab (Kevzara™) is a fully human monoclonal antibody that targets IL-6, a protein central to the development of the signs and symptoms of rheumatoid arthritis. Sarilumab can be used alone or in combination with methotrexate or other traditional disease-modifying antirheumatic drugs (DMARDs). It is given by subcutaneous (under the skin) injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program.  Continue reading

Let BC PharmaCare hear “Your Voice” on etanercept SEB

Stick man holding megaphoneBC PharmaCare is looking for your input on etanercept SEB for the treatment of rheumatoid arthritis and ankylosing spondylitis

Etanercept SEB is a subsequent entry biologic version of etanercept (Enbrel). Etanercept SEB is used for treating people with moderate to severe rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and works by targeting the tumor necrosis factor alpha (TNFA) molecule. It is given by subcutaneous injection.

A SEB needs to have the same mechanism of action as the originator biologic it was compared to, which means it should work in a similar way. Health Canada defines SEBs as a “biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug.” Continue reading

Let BC PharmaCare hear “Your Voice” on secukinumab

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on secukinumab for the treatment of ankylosing spondylitis and psoriatic arthritis

Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection. The drug is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about secukinumab for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA).

You can give input if you are a B.C. resident and have AS or PsA, a caregiver to someone with AS or PsA, or if your group represents people who live with AS or PsA.

The submission deadline is midnight on July 21, 2016. Patients and caregivers may give their input directly through the links below.
Continue reading

Let BC PharmaCare hear “Your Voice” on canakinumab

Megaphone GraphicBC PharmaCare is looking for your input on canakinumab for the treatment of systemic juvenile idiopathic arthritis (sJIA)

Canakinumab (Ilaris®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about canakinumab for the treatment of sJIA.

You can give input if you are a B.C. resident and have sJIA, a caregiver to someone with sJIA, or if your group represents people who live with sJIA.

The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading

JointHealth™ Survey on BC PharmaCare policy

Check

JointHealth™ Survey on BC PharmaCare policy

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy.

Arthritis Consumer Experts (ACE) is asking for your valuable feedback on new BC PharmaCare policy. Gathering your views is very important to the advocacy work that we do on your behalf.

This survey includes 13 questions for people living with arthritis and will take approximately 10 minutes to complete. Your participation will be anonymous and the results will be pooled for analysis to assure your complete privacy. Your responses will in no way impact on your health care or public health insurance coverage.

Thank you for taking the time to participate in this important survey. Your feedback helps us to improve the quality and relevance of Arthritis Consumer Experts’ work.

If you have any questions or comments, please contact us at: feedback@jointhealth.org.